Kim Tae-Hyung, Woo Sungmin, Ebrahimzadeh Sanam, McInnes Matthew D F, Gerst Scott R, Do Richard K
Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065.
Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
AJR Am J Roentgenol. 2023 Jan;220(1):28-38. doi: 10.2214/AJR.22.27989. Epub 2022 Aug 3.
Accumulating evidence indicates that hepatocellular adenoma (HCA) may have a higher frequency of hepatobiliary phase (HBP) iso- or hyperintensity than previously reported. The purpose of this study was to evaluate the proportion of HCA that shows iso- or hyperintensity in the HBP of gadoxetic acid-enhanced MRI, stratified by HCA subtype (-inactivated [H-HCA], inflammatory [I-HCA], β-catenin-activated [B-HCA], and unclassified [U-HCA] HCA), and to assess the diagnostic performance of HBP iso- or hyperintensity for differentiating focal nodular hyperplasia (FNH) from HCA. PubMed, Embase, and Cochrane Central Register of Controlled Trials were searched through February 14, 2022, for articles reporting HBP signal intensity on gadoxetic acid-enhanced MRI among pathologically proven HCAs, stratified by subtype. The pooled proportion of HBP iso- or hyperintensity was determined for each subtype and compared using metaregression. Diagnostic performance of HBP iso- or hyperintensity for differentiating FNH from all HCA subtypes combined and from B-HCA and U-HCA combined was assessed using bivariate modeling. Twenty-eight studies (12 original investigations, 16 case reports or case series) were included, yielding 364 patients with 410 HCAs (112 H-HCAs, 203 I-HCAs, 33 B-HCAs, 62 U-HCAs). Pooled proportion of HBP iso- or hyperintensity was 14% (95% CI, 4-26%) among all HCAs, 0% (95% CI, 0-2%) among H-HCAs, 11% (95% CI, 0-29%) among U-HCAs, 14% (95% CI, 2-31%) among I-HCAs, and 59% (95% CI, 26-88%) among B-HCAs; metaregression showed significant difference among subtypes ( < .001). In four studies reporting diagnostic performance information, HBP iso- or hyperintensity had sensitivity of 99% (95% CI, 57-100%) and specificity of 89% (95% CI, 82-94%) for differentiating FNH from all HCA subtypes and sensitivity of 99% (95% CI, 53-100%) and specificity of 65% (95% CI, 44-80%) for differentiating FNH from B-HCA or U-HCA. HCA subtypes other than H-HCA show proportions of HBP iso- or hyperintensity ranging from 11% (U-HCA) to 59% (B-HCA). Low prevalence of B-HCA has contributed to prior reports of high diagnostic performance of HBP iso- or hyperintensity for differentiating FNH from HCA. Radiologists should recognize the low specificity of HBP iso- or hyperintensity on gadoxetic acid-enhanced MRI for differentiating FNH from certain HCA subtypes.
越来越多的证据表明,肝细胞腺瘤(HCA)在肝胆期(HBP)出现等信号或高信号的频率可能比先前报道的更高。本研究的目的是评估在钆塞酸增强MRI的HBP中表现为等信号或高信号的HCA比例,并按HCA亚型(失活型[H-HCA]、炎症型[I-HCA]、β-连环蛋白激活型[B-HCA]和未分类[U-HCA] HCA)进行分层,同时评估HBP等信号或高信号在鉴别局灶性结节性增生(FNH)与HCA方面的诊断性能。通过检索截至2022年2月14日的PubMed、Embase和Cochrane对照试验中心注册库,查找有关经病理证实的HCA中钆塞酸增强MRI上HBP信号强度的文章,并按亚型进行分层。确定每种亚型HBP等信号或高信号的合并比例,并使用Meta回归进行比较。使用双变量模型评估HBP等信号或高信号在鉴别FNH与所有合并的HCA亚型以及与合并的B-HCA和U-HCA方面的诊断性能。纳入了28项研究(12项原始研究、16项病例报告或病例系列),共364例患者,410个HCA(112个H-HCA、203个I-HCA、33个B-HCA、62个U-HCA)。所有HCA中HBP等信号或高信号的合并比例为14%(95%CI,4-26%),H-HCA中为0%(95%CI,0-2%),U-HCA中为11%(95%CI,0-29%),I-HCA中为14%(95%CI, 2-31%),B-HCA中为59%(95%CI,26-88%);Meta回归显示各亚型之间存在显著差异(P<0.001)。在4项报告诊断性能信息的研究中,HBP等信号或高信号在鉴别FNH与所有HCA亚型时的敏感性为99%(95%CI,57-100%),特异性为89%(95%CI,82-94%);在鉴别FNH与B-HCA或U-HCA时的敏感性为99%(95%CI,53-100%),特异性为65%(95%CI,44-80%)。除H-HCA外的HCA亚型中,HBP等信号或高信号的比例在11%(U-HCA)至59%(B-HCA)之间。B-HCA的低患病率导致先前报道HBP等信号或高信号在鉴别FNH与HCA方面具有较高的诊断性能。放射科医生应认识到钆塞酸增强MRI上HBP等信号或高信号在鉴别FNH与某些HCA亚型时特异性较低。